Clinical trials: Androgen Deprivation Therapy
Metastatic Prostate Cancer
The Effect of Metformin in Patients With Newly Diagnosed mHSPC
The purpose of this study is to assess the effect of the addition of metformin to abiraterone on survival in patients with newly diagnosed metastatic hormone-sensitive prostate cancer.
- Trial name
- NCT04925063
- Testing
- Metformin
- Where
- China
- Volunteers
- 266 people
- Sponsor
- Sun Yat-sen University
Prostate Cancer
Androgen Suppression Plus Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Androgens can cause the growth of prostate cancer cells. Drugs, such as leuprolide, goserelin, flutamide, or bicalutamide, may stop the adrenal glands from making androgens.
- Trial name
- NCT00006359
- Testing
- LHRH agonist, antiandrogen, radiation therapy
- Where
- 26 sites in United States
- Volunteers
- 63 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Prostate Cancer
The Effect of Androgen Deprivation Therapy on Gut and Urinary Microbiota in Patients With Prostate Cancer
The incidence of prostate cancer is increasing in Hong Kong, as well as that of recurrent or metastatic prostate cancer. Androgen deprivation therapy (ADT) is the standard treatment for recurrent or metastatic prostate cancer…
- Trial name
- NCT03888742
- Where
- Hong Kong
- Volunteers
- 214 people
- Sponsor
- Chinese University of Hong Kong
Localized Prostate Carcinoma, Castration-Naive Prostate Cancer
Neoadjuvant ADT With TULSA in the Treatment of Intermediate Risk Prostate Cancer
Clinical studies have shown that magnetic resonance imaging-guided transurethral ultrasound ablation (TULSA) of the prostate is safe and effective. In the TULSA procedure, prostate tissue is killed by heating with ultrasound.
- Conditions
- Localized Prostate Carcinoma, Castration-Naive Prostate Cancer, Intermediate Risk Prostate Cancer, Prostate Cancer
- Trial name
- NeoADT-TULSA (NCT05917860)
- Testing
- Degarelix, MRI-guided transurethral ultrasound ablation (TULSA)
- Where
- Finland
- Volunteers
- 15 people
- Sponsor
- Turku University Hospital
Metastatic Castration-Resistant Prostate Cancer, mCRPC
REGN21353 Alone or in Combination With Nezastomig for Metastatic Castration-Resistant Prostate Cancer in Adult Participants
This study will test an experimental Regeneron drug called REGN21353 ("study drug") to see if it can help treat previously treated prostate cancer that has spread (also called metastatic castration-resistant prostate cancer or…
- Trial name
- NCT07850921
- Testing
- REGN21353, Nezastomig, Sarilumab Prophylaxis (Contingency)
- Volunteers
- 192 people
- Sponsor
- Regeneron Pharmaceuticals
Prostate Cancer
A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery
Patients with post-prostatectomy PSA (Prostate Specific Antigen) recurrences with aggressive disease features will receive salvage radiation therapy and standard androgen deprivation therapy (ADT) or enhanced ADT to determine if…
- Trial name
- STEEL (NCT03809000)
- Testing
- Radiation Therapy, Enzalutamide, Bicalutamide
- Where
- 108 sites in United States, Canada
- Volunteers
- 188 people
- Sponsor
- RTOG Foundation, Inc.
Prostate Carcinoma
Computer-Based Behavior Change Guide in Increasing Physical Activity in Patients With Prostate Cancer Who Have Received Androgen Deprivation Therapy
This randomized pilot clinical trial studies how well a computer-based behavior change guide works in increasing physical activity in patients with prostate cancer who have received androgen deprivation therapy.
- Trial name
- NCT02869412
- Testing
- Computer-Assisted Intervention, Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- OHSU Knight Cancer Institute
Prostate Cancer
Biomarker Monitoring of Prostate Cancer Patients With RSI MRI (ProsRSI)
Adult male patients with high-risk, localized prostate cancer and planning to undergo radiation therapy (RT) with androgen deprivation therapy (ADT) will undergo an advanced Magnetic Resonance Imaging (MRI) examination called…
- Trial name
- ProsRSI (NCT04349501)
- Testing
- Restriction Spectrum Imaging Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of California, San Diego
Prostatic Neoplasm, Osteoporosis
Exercise for Physical Health in Men With Prostate Cancer
The purpose of this study is to conduct a 12-month randomized controlled trial comparing the effects of strength and impact exercise training to flexibility/relaxation training on body composition (bone, muscle and fat mass)…
- Trial name
- NCT00660686
- Testing
- Resistance Exercise, Flexibility Training
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- OHSU Knight Cancer Institute
Prostate Cancer
Study of External Beam Radiation Therapy With and Without Hormonal Therapy to Treat Prostate Cancer
This clinical study was to determine if the use of 6 months of total androgen suppression (hormonal therapy) when added to radiation therapy for localized-high risk prostate cancer would improve overall survival.
- Trial name
- NCT00116220
- Testing
- Flutamide (Eulexin) and Lupron or Zoladex, External Beam Radiotherapy
- Where
- United States
- Volunteers
- 206 people
- Sponsor
- Dana-Farber Cancer Institute
Prostate Adenocarcinoma
Supportive Therapy in Androgen Deprivation Clinic in Improving Health Outcomes and Managing Side Effects in Patients With Prostate Cancer
This pilot partially-randomized phase II trial studies how well Supportive Therapy in Androgen Deprivation (STAND) clinic works in improving health outcomes and managing side effects in patients with prostate cancer.
- Trial name
- NCT02168062
- Testing
- Behavioral Dietary Intervention, Counseling, Educational Intervention
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- University of California, San Francisco
Metastatic Prostate Cancer
Biomarkers of Bone Resorption in Metastatic Prostate Cancer
Biomarkers of bone resorption will be measured in the blood of patients with bone metastases from prostate cancer during the course of their illness.
- Trial name
- NCT01233557
- Where
- United Kingdom
- Volunteers
- 40 people
- Sponsor
- University of Aberdeen
Solid Tumours
Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy in Participants With Castrate-resistant Prostate Cancer
This study aims to evaluate the combination of GSK525762 with other agents that have been shown to be effective in the treatment of CRPC or metastatic (m)CRPC.
- Trial name
- NCT03150056
- Testing
- GSK525762, Abiraterone, Enzalutamide
- Where
- 20 sites in United States, Australia and 2 more
- Volunteers
- 73 people
- Sponsor
- GlaxoSmithKline
Cancer of the Prostate
Eligard Observational Registry for Patients With Prostate Cancer
The objective of this registry is to collect data on patient demographics, medical history, change in prostate, bone and overall health of the patients receiving androgen ablation treatment using Eligard.
- Trial name
- NCT00992251
- Where
- 36 sites in Canada
- Volunteers
- 354 people
- Sponsor
- CMX Research
Prostate Cancer
SWOG-9346, Hormone Therapy in Treating Men With Stage IV Prostate Cancer
RATIONALE: Testosterone can stimulate the growth of prostate cancer cells. Hormone therapy may be effective treatment for prostate cancer.
- Trial name
- NCT00002651
- Testing
- bicalutamide, goserelin acetate, clinical observation
- Where
- 14 sites in Canada
- Volunteers
- 3,040 people
- Sponsor
- SWOG Cancer Research Network
Prostate Adenocarcinoma, Stage I Prostate Cancer
Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer
This phase II trial studies how well androgen deprivation therapy and vorinostat followed by radical prostatectomy works in treating patients with prostate cancer that has not spread to other parts of the body.
- Conditions
- Prostate Adenocarcinoma, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer
- Trial name
- TARGET (NCT00589472)
- Testing
- Bicalutamide, Goserelin Acetate, Laboratory Biomarker Analysis
- Where
- 15 sites in United States
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
A Study of Stereotactic Body Radiation Therapy (SBRT) Without Androgen Deprivation Therapy (ADT) in People With Unfavorable Intermediate-Risk Prostate Cancer
The researchers are doing this study to find out if stereotactic body radiation therapy (SBRT) without androgen deprivation therapy (ADT) is an effective treatment approach for people with unfavorable intermediate-risk prostate.
- Trial name
- NCT05169970
- Testing
- Stereotactic Body Radiation Therapy (SBRT)
- Where
- 7 sites in United States
- Volunteers
- 222 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Hormone-sensitive Prostate Cancer (mHSPC), Prostate Cancer
Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer
The purpose of this study is to study the effects of EPI-7386 in combination with Enzalutamide on participants diagnosed with prostate cancer.
- Conditions
- Metastatic Hormone-sensitive Prostate Cancer (mHSPC), Prostate Cancer, Prostate Adenocarcinoma
- Trial name
- NCT06312670
- Testing
- EPI-7386, Enzalutamide, Androgen Deprivation Therapy (ADT)
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Pedro Barata, MD, MSc
Prostate Cancer
Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer
RATIONALE: Hormones can stimulate the production of prostate cancer cells. Hormone therapy may fight prostate cancer by reducing the production of androgens. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00004054
- Testing
- bicalutamide, estramustine phosphate sodium, etoposide
- Where
- 54 sites in United States, Canada
- Volunteers
- 397 people
- Sponsor
- Radiation Therapy Oncology Group
Castrate Sensitive Prostate Cancer
Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer
Background: Prostate cancer is a common cancer among men. There are several ways to treat it, including hormone blocking drugs, radiation therapy, and surgery.
- Trial name
- NCT03860987
- Testing
- goserelin, Enzalutamide, Abiraterone
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)